GIT27

Name	2-(3-Phenyl-4,5-dihydroisoxazol-5-yl)acetic Acid
Synonyms	GIT27 GIT27 GIT 27 GIT-27 CS-1488 VGX1027 VGX-1027 VGX 1027 VGX-1027(GIT 27) VGX-1027 ( GIT 27) 4,5-Dihydro-3-phenyl-5-isoxazoleaceticacid 4,5-DIHYDRO-3-PHENYL-5-ISOXAZOLEACETICACID 2-(3-Phenyl-4,5-dihydroisoxazol-5-yl)acetic Acid 2-(3-PHENYL-4,5-DIHYDROISOXAZOL-5-YL)ACETIC ACID 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid
CAS	6501-72-0

Molecular Formula	C11H11NO3
Molar Mass	205.21
Melting Point	157-158℃
Solubility	Soluble in DMSO (up to 30 mg/ml).
Appearance	solid
Color	White
Storage Condition	Sealed in dry,2-8°C
Stability	Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
In vitro study	VGX-1027 significantly inhibited IL-1β/IFN-γ induced TNF-α and nitrite accumulation, and significantly increased cell survival by interfering with the toxic effects of cytokines. VGX-1027 inhibition of intestinal bacterial antigen-reactive CD4 CD25 -T cell proliferation in vitro.
In vivo study	VGX-1027 prevents the development of spontaneous type I diabetes in NOD mice and counteracts the acceleration of diabetes induced by cyclophosphamide challenge or adoptive transfer of diabetic splenocytes in NOD mice. VGX-1027 also reduced the clinical signal of diabetes induced by MLD-STZ and inhibited histopathological changes in the pancreas. VGX-1027 inhibits the clinical, histological, and immunological development of DNBS-induced colitis in CD1 mice. In the NZB/ NZW F1 model of systemic lupus erythematosus (SLE), VGX-1027 improved symptoms of the disease, improved survival, and improved clinical and histopathological signals.

Hazard Symbols	Xn - Harmful
Risk Codes	R22 - Harmful if swallowed R43 - May cause sensitization by skin contact
Safety Description	36/37 - Wear suitable protective clothing and gloves.